<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>26(6)</volume><submitter>Neuber C</submitter><pubmed_abstract>The inducible enzyme cyclooxygenase-2 (COX-2) and the subsequent synthesis of eicosanoids initiated by this enzyme are important molecular players in bone healing. In this pilot study, the suitability of a novel selective COX-2 inhibitor bearing a nitric oxide (NO)-releasing moiety was investigated as a modulator of healing a critical-size bone defect in rats. A 5 mm femoral defect was randomly filled with no material (negative control, NC), a mixture of collagen and autologous bone fragments (positive control, PC), or polycaprolactone-co-lactide (PCL)-scaffolds coated with two types of artificial extracellular matrix (aECM; collagen/chondroitin sulfate (Col/CS) or collagen/polysulfated hyaluronic acid (Col/sHA3)). Bone healing was monitored by a dual-tracer ([&lt;sup>18&lt;/sup>F]FDG/[&lt;sup>18&lt;/</pubmed_abstract><journal>International journal of molecular sciences</journal><pagination>2582</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11942287</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Exploring a Nitric Oxide-Releasing Celecoxib Derivative as a Potential Modulator of Bone Healing: Insights from Ex Vivo and In Vivo Imaging Experiments.</pubmed_title><pmcid>PMC11942287</pmcid><pubmed_authors>Pietzsch J</pubmed_authors><pubmed_authors>Niedenzu L</pubmed_authors><pubmed_authors>Schulze S</pubmed_authors><pubmed_authors>Rammelt S</pubmed_authors><pubmed_authors>Hofheinz F</pubmed_authors><pubmed_authors>Neuber C</pubmed_authors><pubmed_authors>Laube M</pubmed_authors></additional><is_claimable>false</is_claimable><name>Exploring a Nitric Oxide-Releasing Celecoxib Derivative as a Potential Modulator of Bone Healing: Insights from Ex Vivo and In Vivo Imaging Experiments.</name><description>The inducible enzyme cyclooxygenase-2 (COX-2) and the subsequent synthesis of eicosanoids initiated by this enzyme are important molecular players in bone healing. In this pilot study, the suitability of a novel selective COX-2 inhibitor bearing a nitric oxide (NO)-releasing moiety was investigated as a modulator of healing a critical-size bone defect in rats. A 5 mm femoral defect was randomly filled with no material (negative control, NC), a mixture of collagen and autologous bone fragments (positive control, PC), or polycaprolactone-co-lactide (PCL)-scaffolds coated with two types of artificial extracellular matrix (aECM; collagen/chondroitin sulfate (Col/CS) or collagen/polysulfated hyaluronic acid (Col/sHA3)). Bone healing was monitored by a dual-tracer ([&lt;sup>18&lt;/sup>F]FDG/[&lt;sup>18&lt;/</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Mar</publication><modification>2025-07-02T03:04:39.659Z</modification><creation>2025-07-02T03:04:39.659Z</creation></dates><accession>S-EPMC11942287</accession><cross_references><pubmed>40141223</pubmed><doi>10.3390/ijms26062582</doi></cross_references></HashMap>